جست‌وجوی استاد و پژوهشگر

Matthew Childمشاهده پروفایل

عضو هیئت علمی

• Biochemistry
• Cell Biology
• Microbiology
• +۶ مورد دیگر

Dr. Matthew Child is a Senior Research Fellow in the Department of Life Sciences at Imperial College London's Faculty of Natural Sciences. His lab focuses on understanding how amino acids contribute to protein function in live cells, particularly in the context of rare diseases and infections by pathogens. Key affiliations include the Imperial College Network of Excellence in Malaria, Institute of Chemical Biology, and the CDT in Chemical Biology program. He leads the Child Lab, which combines cutting-edge techniques to address novel scientific questions in parasite biology and chemical biology. Matthew holds a PhD in molecular parasitology from the National Institute for Medical Research (London, UK) and conducted postdoctoral research at Stanford University under Prof. Matt Bogyo. In 2016, he established his independent lab at Imperial College with support from a Wellcome Trust and Royal Society Sir Henry Dale Fellowship. His research spans protein function analysis, drug discovery targeting pathogens like Toxoplasma and Plasmodium, and developing AAV-based gene therapy vectors for neurological applications. Research interests include: functional proteomics, redox signaling in parasites, antivirulence agents for Clostridium difficile, and engineering AAV capsids to enhance brain targeting. The lab employs CRISPR-based recombineering, activity-based proteomics, and in vivo barcoding to study pathogen biology and therapeutic targets. Collaborations include the Institute of Chemical Biology and the Imperial College Chemical Biology CDT. Notable achievements include the discovery of ALPL as a BBB-penetrant AAV receptor, development of TRACER AAV capsids evading pre-existing antibodies, and elucidating malaria parasite immune evasion mechanisms. The lab's work is funded through competitive grants and maintains a strong focus on translating fundamental discoveries into clinical and therapeutic applications.

Bradley Bernsteinمشاهده پروفایل

استاد

• Epigenetics
• Cancer Biology
• Chromatin Regulation
• +۳ مورد دیگر

Bradley Bernstein, M.D., Ph.D., is a Professor of Pathology and Cell Biology at Harvard Medical School and Chair of Cancer Biology at Dana-Farber Cancer Institute. He holds the Richard and Nancy Lubin Family Chair and directs the Broad Institute’s Gene Regulation Observatory and Epigenomics Program. His research focuses on epigenetic mechanisms in development and cancer, including chromatin regulation, bivalent domains, and cancer epigenetics. He has pioneered technologies like ENCODE and advanced understanding of noncoding DNA’s role in gene regulation. His work spans cancer mechanisms, stem cell circuits, and therapeutic resistance. Notable contributions include identifying bivalent chromatin states and linking epigenetic changes to oncogene activation in gliomas. Education: B.S. from Yale University (1992), M.D. and Ph.D. from University of Washington (1999), postdoctoral training at Harvard University. Affiliations include Dana-Farber Cancer Institute, Broad Institute, and Ludwig Institute. Research Interests: Epigenetic gene regulation, chromatin structure, cancer epigenetics, developmental hierarchies, single-cell technologies, and translational applications in oncology. Key areas include bivalent domains, tumor self-renewal, and epigenetic therapies. Awards: Richard and Nancy Lubin Family Chair, Ludwig Institute Investigator. Advising & Grants: Mentor to numerous graduate students and postdocs. Leads large-scale consortia (e.g., ENCODE, BLUEPRINT). Active in technology development for epigenomic mapping. Labs/Teams: Bernstein Lab at Dana-Farber and Broad Institute, Epigenomics Program, and Gene Regulation Observatory. Collaborates widely across academia and industry.

• Gene Silencing
• RNAi
• Genomics
• +۵ مورد دیگر

Professor Peter Waterhouse is a leading molecular geneticist at Queensland University of Technology (QUT), holding dual roles as Professor of Molecular Genetics and Australian Laureate Fellow. He is affiliated with QUT’s Faculty of Science (School of Biology & Environmental Science) and serves as Program Leader at the Australian Research Council (ARC) Centre of Excellence for Plant Success in Nature and Agriculture. A Fellow of the Australian Academy of Science and recipient of the Prime Minister’s Prize for Science (2007), his work spans RNA interference (RNAi), plant genomics, and epigenetics. Education: BSc (Hons) in Plant Biology from the University of Newcastle upon Tyne (1977), PhD in Plant Virology from the University of Dundee (1981). Career highlights include leadership roles at CSIRO Plant Industry, ARC Federation Fellowships (2008–2013), and honorary professorships at the University of Sydney. He has pioneered RNAi research with over 150 peer-reviewed publications (>20,000 citations, h-index >65). Research focuses on gene silencing mechanisms, viral biology, and plant biotechnology. Notable contributions include patents on RNAi applications, recombinant antibodies, and virus-resistant plants. His work bridges fundamental science with commercialization, exemplified by collaborations with industry partners like Bayer and Cambridge Antibody Technology Ltd. Awards: Prime Minister’s Prize for Science, CSIRO Chairman’s Medal, Victor Chang Medal Patents: 11 RNAi-related patent families, recombinant antibody patents, and plant resistance patents Leadership: Scientific advisory roles for organizations including the Prime Minister’s Science Council and the Ramaciotti Centre for Gene Function Analysis His recent publications emphasize multi-omic analyses of Nicotiana benthamiana, viral resistance mechanisms, and drought response strategies in plants. Ongoing work explores terminator elements to enhance transgene expression and improve biotechnological applications.

Klemens J. Hertelمشاهده پروفایل

استاد

• Alternative Splicing
• RNA Processing
• Molecular Genetics
• +۳ مورد دیگر

Klemens J. Hertel is a Professor and Chair of the Department of Microbiology & Molecular Genetics at the University of California, Irvine School of Medicine. His research focuses on the molecular mechanisms of RNA splicing, particularly the regulation of alternative splicing events such as NAGNAG splicing and their implications in cancer and cellular processes. He has contributed extensively to understanding spliceosome dynamics, RNA processing, and the interplay between splicing and gene regulation. Key research areas include the influence of genetic and epigenetic factors on splicing efficiency, the role of RNA-binding proteins in splice site selection, and the impact of metabolic signals on alternative splicing. His work integrates biochemical assays, high-throughput sequencing, and computational modeling to uncover fundamental mechanisms in molecular genetics. Recent studies highlight his exploration of splicing defects in cancer progression, the regulatory networks governing spliceosome assembly, and the functional consequences of alternative polyadenylation. He has published over 50 peer-reviewed articles, with notable contributions to journals like Nucleic Acids Research and Molecular and Cellular Biology. Dr. Hertel’s grants include NIH funding (R01 GM062287, R21 CA149548) for projects on splicing regulation and cancer biology. His lab is at the forefront of developing in vitro splicing systems and tools for studying RNA processing. Mentorship of students and postdocs in molecular genetics and biochemistry underscores his commitment to training future scientists.

Jordan J. Greenمشاهده پروفایل

استاد

• Nanobiotechnology
• Biomaterials
• Drug Delivery
• +۵ مورد دیگر

Jordan J. Green, PhD, is a Professor in the Department of Biomedical Engineering at Johns Hopkins University, with affiliations to the Whiting School of Engineering and the Johns Hopkins School of Medicine. His research focuses on biomaterials, drug delivery systems, gene therapy, nanobiotechnology, and immunotherapy, with applications in oncology, regenerative medicine, and ophthalmology. His Biomaterials and Drug Delivery Laboratory develops innovative technologies to address unmet clinical needs, such as cancer treatment, immune modulation, and targeted delivery of therapeutics. Key research areas include nanoparticle design for siRNA and DNA delivery, biomimetic artificial antigen-presenting cells for cancer immunotherapy, and suprachoroidal gene delivery for retinal diseases. Dr. Green’s work bridges the chemistry-biology-engineering interface, emphasizing translational applications to improve human health. Recent studies highlight advancements in polymeric nanoparticle formulations, tumor microenvironment engineering, and radiosensitization strategies for glioblastoma. Publications reflect a focus on nanomedicine, immunomodulation, and targeted therapies, with notable contributions to polymeric nanoparticle systems and biomaterial-mediated genetic reprogramming. Collaborations span academia and industry, driving preclinical and clinical translation of technologies. Dr. Green’s group also explores multiplexed immunofluorescence imaging and machine learning for optimizing therapeutic strategies. His lab maintains the Biomaterials and Drug Delivery Laboratory, emphasizing interdisciplinary innovation. While specific awards are not listed, his extensive publication record and leadership in biomedical engineering underscore his contributions to the field.

Nikki Copelandمشاهده پروفایل

مدرس ارشد

• DNA Replication
• Cancer Biology
• Genome Stability
• +۳ مورد دیگر

Dr. Nikki Copeland is a Senior Lecturer in Biomedicine and Director of Studies in Biomedical Science at Lancaster University's Faculty of Health and Medicine. She leads research on DNA replication mechanisms in mammalian cells, focusing on cancer-related mutations and genome instability. Her work explores replication licensing, initiation processes, and differences between cancerous and normal tissues to identify therapeutic targets. Her research employs cell-based and cell-free DNA replication techniques to study regulatory steps in replication. Key projects include analyzing CIZ1's role in cell cycle regulation and Ap4A's impact on DNA replication under stress. She has supervised students such as Megan Fraser and Hend Abdelrady Mohamed Abdelmohsen on topics ranging from 3D cell models to biomaterials in drug delivery. Recent publications (2024) highlight structural analyses of viral RNA modifications and CIZ1's regulation of G1 phase length. Earlier work (2011-2020) addressed Ap4A signaling, CRISPR mutation detection, and NUDT2's role in immune response modulation. Dr. Copeland's lab focuses on cancer biology and genome stability, collaborating with interdisciplinary teams on biomaterials and drug delivery systems. Her research has implications for developing targeted cancer therapies and diagnostic tools.

André Fischerمشاهده پروفایل

استاد

• Neurodegenerative Diseases
• Epigenetics
• Alzheimer's Disease
• +۳ مورد دیگر

Prof. Dr. André Fischer is a W3 Professor at the Department for Psychiatry and Psychotherapy, University Medical Center Göttingen, and serves as Speaker of the German Center for Neurodegenerative Diseases (DZNE) site Göttingen. His research focuses on epigenetic mechanisms underlying neurodegenerative diseases like Alzheimer's, combining patient and mouse models with molecular, genetic, and bioinformatic techniques. Education & Career: 2003-2006: Postdoctoral Associate at Harvard Medical School and MIT's Picower Center 2007-2011: Independent Group Leader at ENI Since 2011: W3 Professor and DZNE Site Speaker Research Interests: His work explores how gene-environment interactions via epigenetic processes (histone modification, DNA methylation, non-coding RNAs) contribute to neurodegenerative and psychiatric diseases. Key areas include memory formation, neuroprotective therapies, and molecular pathways governing cognitive decline. Publications: His articles highlight breakthroughs in HDAC6 inhibition for Alzheimer's, microRNA-based dementia therapies, and epigenetic regulation of fear memory extinction. These studies underscore his lab's interdisciplinary approach to translational neuroscience. Affiliations: Active in the Göttingen Graduate Center's programs on Molecular Biology, Neuroscience, and Computational Neuroscience. Collaborates across departments to advance neurodegenerative disease research.

Igor I. Slukvinمشاهده پروفایل

استاد

• Hematopoietic stem cell biology
• Induced pluripotent stem cell (iPSC) research
• Vascular and endothelial cell development
• +۴ مورد دیگر

Igor I. Slukvin is a Professor in the Department of Pathology and Laboratory Medicine at the University of Wisconsin–Madison. He holds joint appointments in Cell & Regenerative Biology and is an affiliate scientist at the Wisconsin National Primate Center. His research focuses on hematopoietic and endothelial development from human pluripotent stem cells (PSCs), aiming to advance bone marrow transplantation , transfusion medicine , and cancer immunotherapy . Slukvin’s work has identified cellular pathways for generating hematopoietic progenitors, endothelial cells, and mesenchymal stromal cells from PSCs. He pioneered transgene-free iPSC reprogramming and developed protocols for scalable blood cell production . His lab’s articles highlight innovations in immunotherapy (e.g., anti-GD2 CAR macrophages), preclinical NHP models , and genetic engineering to combat diseases like AIDS and leukemia. His research employs genomics , proteomics , and bioinformatics to dissect molecular mechanisms in blood cell specification. Current projects include creating definitive lympho-myeloid hematopoiesis models, iPSC-based bone marrow therapies , and cancer immunotherapies . The lab’s comparative analysis of fetal and PSC-derived blood cells informs drug discovery and therapeutic strategies.

Robert E. Braunمشاهده پروفایل

استاد

• Germline Stem Cell Biology
• Spermatogenesis
• Testis Development
• +۴ مورد دیگر

Robert E. Braun is the Janeway Distinguished Chair and Professor of Mammalian Genetics at the Graduate School of Biomedical Science and Engineering (University of Maine). His research focuses on germline stem cell biology, spermatogenesis, and molecular regulation of testis development. Research Themes Stem cell fate decisions in gamete development Testosterone signaling in Sertoli cell dynamics Translational gene regulation in germ cells Mechanisms of blood-testis barrier maintenance Publications reveal expertise in mouse genetic models, chromatin modification (SIN3A), and nuclear receptor signaling (Nr4a1). His work combines forward/reverse genetics with advanced microscopy and biochemical analysis. Honors Janeway Distinguished Chair NIH R00 HD055330 funding 5R00HD055330-05 project leadership Advising : Mentored student Sri Pullagura on spermatogonial differentiation. Collaborates with teams studying germ cell tumors and retinoic acid signaling.

Dustin Updikeمشاهده پروفایل

دانشیار

• Germ Cell Biology
• Germ Granules
• Totipotency
• +۳ مورد دیگر

Dustin Updike is an Associate Professor at the Graduate School of Biomedical Science and Engineering (University of Maine). His research focuses on the biophysical properties of germ granules and their role in maintaining germline totipotency and cellular immortality using Caenorhabditis elegans as a model organism. Education: B.S. in Molecular Biology, University of Wyoming (1999) PhD in Human Genetics, University of Utah (2006) Updike’s work investigates how germ granules —conserved structures across species—act as cytoplasmic regulators of gene expression. His lab examines their role in nuclear pore complex interactions , post-transcriptional processing , and potential applications in stem cell biology . Using C. elegans , his team leverages genetic tools and fluorescence microscopy to dissect granule assembly and function. His 15 most recent publications (2015–2025) reveal a consistent focus on germ granule components , RNA regulatory mechanisms , and germline-specific epigenetic pathways . Key subfields include phase separation dynamics , translational repression , and cross-species conservation of granule functions. Grants: NIH/NIGMS R01 (2015–present): Function of germ granules in maintaining germline pluripotency COBRE Grant (2013–2015): Germ granules in cellular self-renewal Service: GSBSE Admissions Committee (2012–2015) MDI Bio Lab Seminar Speaker Committee Chair (2013–2015) Outreach Instructor in CRISPR/Cas9 and developmental genetics (2014–present)

Damián Refojoمشاهده پروفایل

پژوهشگر

• Neuroscience
• Molecular Biology
• Neurodegenerative Diseases
• +۳ مورد دیگر

Damián Refojo is a Medical Doctor and Ph.D. in Biological Sciences from the University of Buenos Aires. He currently serves as the Director of IBioBA – CONICET – MPSP and leads a research group in Molecular Neurobiology. He is also an International Max Planck Fellow and former head of the Max Planck Junior Group in Munich. Education: Medical Doctor (UBA), Ph.D. in Biological Sciences (UBA, 2005), Postdoctoral training at Max Planck Institute of Psychiatry (2006–2008). Affiliations: Director at IBioBA, affiliated with Helmholtz Zentrum München, and collaborator at the Max Planck Institute of Psychiatry. His research focuses on molecular mechanisms underlying neurodegeneration, RNA biology, and stress response pathways. Key topics include circular RNA functions, synaptic plasticity, and neuroendocrine signaling. Publications span advanced topics like CRH signaling, RNA circularity, and neurodegenerative genetics, reflecting interdisciplinary approaches in molecular neuroscience and genetics. Scientific Awards: Max Planck Junior Group Award (2008), International Max Planck Fellow. Refojo’s work integrates proteomic profiling, nanoscopy techniques, and genetic analysis to advance understanding of nervous system disorders.

• Computational Chemistry
• Structural Biology
• Biophysics
• +۳ مورد دیگر

Tamar Schlick is a Professor at New York University, affiliated with the Courant Institute of Mathematical Sciences and the Department of Chemistry. She holds roles as an Associate (Lead) Editor for the International Journal for Multiscale Computational Engineering and has contributed to numerous journals. Education: B.S. in Mathematics, Wayne State University (1982) M.S. and Ph.D. in Applied Mathematics, Courant Institute of Mathematical Sciences, NYU (1984 and 1987) Research Interests: Tamar Schlick focuses on biomolecular modeling, chromatin dynamics, RNA structure prediction, and computational methods for understanding biological systems. Her work integrates computational simulations with experimental data to study complex systems like DNA repair mechanisms, histone interactions, and RNA folding pathways. Her research bridges disciplines such as biophysics, biochemistry, and applied mathematics. Articles Trends: Her recent publications emphasize multiscale modeling in chromatin organization, RNA structural prediction using graph theory, and energy landscapes in biomolecular interactions. These studies highlight advancements in computational tools and their applications in understanding fundamental biological processes. Awards: Over 20 awards, including the John Simon Guggenheim Fellowship (2000-2001), American Physical Society Fellow (2005), and Aspen Health Forum Fellow (2007). Recognitions for contributions to computational chemistry, RNA science, and biomolecular modeling. Advising & Grants: While specific student advisees are not listed, her research groups collaborate on projects funded by NIH, NSF, and other agencies. She leads teams advancing computational frameworks like RAGTOP and CHSalign for RNA structure analysis. Labs/Teams: Active in NYU’s Courant Institute and NYU-ECNU Center for Computational Chemistry, focusing on interdisciplinary research in computational biophysics and molecular modeling.

Magnus Lundgrenمشاهده پروفایل

دانشیار

• Microbiology
• Ancient DNA
• CRISPR Technology
• +۳ مورد دیگر

Magnus Lundgren serves as Director of the SciLifeLab Ancient DNA facility at Uppsala University's Department of Organismal Biology, where he holds the academic rank of Docent (Associate Professor). His role involves providing ancient DNA analysis services to researchers globally, bridging historical inquiry with molecular techniques to explore human evolution and ecological changes. Lundgren's research spans microbiology, biotechnology, and ancient DNA analysis. Initially focused on thermophilic microorganisms and CRISPR-Cas systems in archaea, his work evolved toward developing ancient DNA methodologies. Current projects analyze historical societies through genetic evidence, resolving kinship questions and tracing ecological shifts over time. His dual expertise in microbial genetics and historical genomics enables innovative cross-disciplinary applications. Publication trends reveal a strategic shift from fundamental archaeal cell cycle studies (2004-2010) to applied ancient DNA work (2017-2023), with CRISPR technology serving as a consistent thread. Early papers in Cell and PNAS established his expertise in DNA replication, while recent work applies these principles to archaeological samples and historical kinship resolution. No scientific awards were explicitly mentioned in the source text. Through the SciLifeLab facility, Lundgren mentors researchers and supports collaborative projects across Sweden and internationally. The facility provides critical infrastructure for ancient DNA studies, though specific grant details weren't provided. His leadership enables diverse research in evolutionary biology and archaeology. The SciLifeLab Ancient DNA facility operates as a national resource under Lundgren's direction, offering specialized analysis services for archaeological and historical samples. This infrastructure supports interdisciplinary teams studying human migration patterns, historical epidemics, and ecological adaptations through time-resolved genetic data.

• Chronic Myeloid Leukemia
• Leukemic Stem Cell Biology
• Cancer Metabolism
• +۳ مورد دیگر

Dr. Mary Scott is a Research Fellow at the Paul O'Gorman Leukaemia Research Centre within the Wolfson Wohl Cancer Research Centre at the University of Glasgow, focusing on chronic myeloid leukemia (CML) stem cell biology and therapeutic resistance mechanisms. Her research centers on: Metabolic vulnerabilities in leukemic stem cells (arginine dependency, pyruvate anaplerosis) Epigenetic reprogramming and EZH2 inhibition strategies p53-mediated self-renewal pathways in residual CML disease Microenvironment interactions in the bone marrow niche Recent publications reveal a strong trend toward targeting persistent leukemic stem cells through dual metabolic-epigenetic approaches, with increasing emphasis on mitochondrial metabolism and transcriptional reprogramming as therapeutic avenues. Dr. Scott's research is supported by active grants: 2024-2025: Identification of biomarkers predictive of TKI response in CML (Tenovus Scotland) 2023-2026: Functional analysis of leukemia stem cell subtypes in CML (Leukaemia UK) 2014-2017: H3K27 methylation modulation for eradicating TKI-persistent CML stem cells (Blood Cancer UK) She operates within the Paul O'Gorman Leukaemia Research Centre team, utilizing advanced molecular profiling techniques to investigate therapy-resistant CML populations and develop novel eradication strategies.

• Gene Therapy
• RNA Interference
• Molecular Biology
• +۷ مورد دیگر

Dr. Musa Marimani is a Lecturer in the Department of Anatomical Pathology at the University of the Witwatersrand Medical School, Johannesburg, South Africa. He holds a PhD from the same institution. His research focuses on epigenetic mechanisms underlying HIV and tuberculosis (TB) co-infection, particularly how viral and bacterial pathogens disrupt host immunity through epigenetic modifications like methylation, phosphorylation, and acetylation. He explores these mechanisms to develop diagnostic biomarkers and novel therapies. His work also addresses antimicrobial resistance, drug delivery systems, and natural product-based therapeutics. Education : BSc (University of the Witwatersrand) BSc Honours (University of the Witwatersrand) MSc (University of the Witwatersrand) PhD (University of the Witwatersrand) Research Interests : Gene therapy, RNA interference, molecular medicine, and microbiology, with emphasis on HIV-TB co-infection, epigenetic regulation, and antimicrobial resistance. His projects aim to identify therapeutic targets and biomarkers for improved diagnostics and treatment regimens. Publications : His recent work includes studies on epigenetic regulation in co-infected patients, nanoemulsion drug carriers for multi-drug resistance, and natural products against pathogens like Candida auris and Listeria monocytogenes . A notable focus is on host-pathogen interactions and the development of novel therapies to combat drug-resistant infections. Grants/Advising : No specific grants or student advising roles are detailed in the provided information. Labs/Teams : Research conducted within the University of the Witwatersrand’s Medical School, collaborating on interdisciplinary projects in molecular pathology and infectious diseases.